Recent news on Rebetol

Schering-Plough Announces Hepatitis C Data Presentations At ...  -  May 19, 2007
Medical News Today (press release),This second cohort will evaluate the safety and efficacy of boceprevir in combination with PEGINTRON and a lower dose of REBETOL (400-1000 mg daily).

Committee for Medicinal Products for Human Use Post-authorisation ...  -  Apr 27, 2007
PharmaLive.com (press release),Adult patients: Rebetol is indicated, in combination with peginterferon alfa-2b, for the treatment of adult patients with chronic hepatitis C,

Schering-Plough (SGP) Announces Hepatitis C Data Presentations  -  May 18, 2007
StreetInsider.com (subscription),A total of 20 oral and poster presentations on clinical studies with Schering-Plough's (NYSE: SGP)hepatitis products, including PEGINTRON and REBETOL

Market Report -- In Play (WIRES)  -  Apr 30, 2007
MSN MoneyPEGINTRON and REBETOL for the treatment of previously untreated adult patients with chronic hepatitis C who are coinfected with clinically stable HIV.

Schering-Plough presenting Hepatitis C at Digestive Disease Week ...  -  May 19, 2007
SpiritIndia,...including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for chronic hepatitis C virus (HCV) infection,

Schering-Plough Addresses Major Milestones and Challenges in ...  -  Apr 10, 2007
PR Newswire (press release),The primary objective of the study is to evaluate the safety and efficacy of boceprevir 800 mg TID in combination with PEGINTRON and REBETOL in the

PEGINTRON(TM) Approved In China For Treating Chronic Hepatitis B  -  Apr 8, 2007
Medical News Today (press release),Anemia associated with REBETOL therapy may exacerbate cardiac disease that has led to fatal and nonfatal myocardial infarctions. Patients with a history of

PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B  -  Apr 5, 2007
PR Newswire (press release),Important Safety Information Regarding US Labeling for PEGINTRON and REBETOL WARNING Alpha interferons, including PEGINTRON, may cause or aggravate fatal or

Schering-Plough Reaffirms Commitment To Advancing Science And ...  -  Apr 11, 2007
Trading Markets,Schering-Plough noted that among these are several studies with PEGINTRON and REBETOL combination therapy, which is a current standard of care in the

Schering-Plough Reaffirms Commitment To Advancing Science ...  -  Apr 10, 2007
Trading Markets,The company further noted that the several studies with PEGINTRON and REBETOL combination therapy would evaluate how results at important treatment

Medical Edge: Benefits of hepatitis C drugs outweigh side effects  -  Apr 14, 2007
Bryan College Station Eagle,The standard of care for hepatitis C treatment is indeed interferon combined with ribavirin (Rebetol). Interferon (brand name: Peg-Intron or Pegasys) is a

Schering-Plough commits to chronic hepatitis C research  -  Apr 12, 2007
News-Medical.net,Among these are several studies with PEGINTRON (peginterferon alfa-2b) and REBETOL (ribavirin) combination therapy, a current standard of care in the

HIV and Hepatitis Co-Infections Challenging  -  Apr 6, 2007
MedPage Today,...of serum HCV RNA six months after the end of therapy, and the standard of care is pegylated interferon alfa (Pegasys) plus ribivarin (Copegus, Rebetol).

Schering-Plough Reports Financial Results for First Quarter of 2007  -  Apr 19, 2007
PR Newswire (press release),PEGINTRON 217 196 10% CLARINEX / AERIUS 204 160 28% TEMODAR 196 163 20% AVELOX 115 80 43% CLARITIN RX 112 101 11% INTEGRILIN 84 80 6% REBETOL 71 78 (8%)

Medical Edge -- Hepatitis C treatment an ordeal worth enduring  -  Mar 12, 2007
Post-Bulletin,The standard of care for hepatitis C treatment is indeed interferon combined with ribavirin (Rebetol). Interferon (brand name: Peg-Intron or Pegasys) is a

Hep C Help  -  Mar 20, 2007
WFtv.com,Another drug called ribavirin (Copegus, Rebetol, Virazole) is often used along with interferon treatment. Ribavirin can help fight some viruses and is taken

Help for hepatitis C  -  Feb 8, 2007
News 8 Austin,Another drug called ribavirin (Copegus, Rebetol, Virazole) is often used along with interferon treatment. Ribavirin can help fight some viruses and is taken

How to Spot Great Stocks  -  Feb 7, 2007
Motley Fool...(If you're fighting hepatitis, for example, you're probably not going to forgo taking your Rebetol to save a few bucks.) Firms such as Coca-Cola and Kraft

Schering-Plough Reports Financial Results for 2006 Fourth Quarter ...  -  Jan 29, 2007
PR Newswire (press release),AERIUS 164 139 18% 722 646 12% TEMODAR 189 160 18% 703 588 20% CLARITIN RX 78 85 (8%) 356 371 (4%) INTEGRILIN 85 71 20% 329 315 5% REBETOL 75 94 (21%)

FDA Safety Changes: Keppra, Naropin, Rebetol  -  Dec 22, 2006
Medscape (subscription)On August 25, the FDA approved safety label changes for ribavirin capsules and oral solution (Rebetol, made by Schering Corp) to warn of the risk for dental

FDA Safety Changes: Keppra, Naropin, Rebetol  -  Dec 22, 2006
Medscape (subscription)On August 25, the FDA approved safety label changes for ribavirin capsules and oral solution (Rebetol, made by Schering Corp) to warn of the risk for dental

From the analyst's couch: Hepatitis C virus therapies  Sep 8, 2006
...of pegylated interferon-alfa (PEG–IFN) — either 2a (Roche's Pegasys) or 2b (Schering-Plough's PEG-Intron) — and ribavirin (Rebetol (Schering-Plough ... -Nature.com (subscription)

Saving Your Liver  -  Nov 16, 2006
Forbes,...treatment of hepatitis C with its interferon drug, PEG-Intron, which brought in $751 million in sales last year, and a ribavirin drug called Rebetol.

Life After Zocor  Aug 21, 2006
Sales in Schering-Plough's hepatitis C franchise, which includes the off-patent drugs Rebetol and Intron A, increased 7% to $374 million, driven by the launch ... -Chemical & Engineering News

Health & Medicine  Aug 11, 2006
...(WPI). In addition, Schering-Plough (SGP) licensed Rebetol as an authorized generic to its own subsidiary, Warrick Pharmaceuticals. ... -Investor's Business Daily (subscription)

Pegylated Interferon Aids in Post-Transplant HCV  Jul 10, 2006
VALENCIA, Spain, July 10 -- With a combination of pegylated interferon and Rebetol (ribavirin), liver transplant recipients with recurrent hepatitis C (HCV ... -MedPage Today



EU Label Change for Intron A (Interferon Alfa-2b) Incorporates ...  Apr 26, 2006
...pegylated version of interferon alfa-2b called PEG-Intron (peginterferon alfa-2b), for use as monotherapy or in combination therapy with Rebetol(R) (ribavirin ... - DG News

EU Label Change for INTRON(R) A (interferon Alfa-2b) Incorporates ...  Apr 25, 2006
...version of interferon alfa-2b called PEG-INTRON (peginterferon alfa-2b), for use as monotherapy or in combination therapy with REBETOL® (ribavirin, USP) for ... - Yahoo! News

WIN-R Study Demonstrates Efficacy of Shorter PEG-Intron and ...  Apr 28, 2006
C virus (HCV) genotype 2 or 3, a shorter, 24-week course of therapy with PEG-Intron(R) (peginterferon alfa-2b) in combination with Rebetol(R) (ribavirin, USP ... - DG News

Schering-Plough's shorter dose hepatitis regimen shows promise  May 2, 2006
...for patients infected with hepatitis C virus genotype 2 or 3, a shorter, 24-week course of therapy with Schering-Plough's Peg-Intron plus Rebetol was as ... - Pharmaceutical Business Review

WIN-R Study Demonstrates Efficacy of Shorter PEG-INTRON and ...  Apr 28, 2006
C virus (HCV) genotype 2 or 3, a shorter, 24-week course of therapy with PEG-INTRON® (peginterferon alfa-2b) in combination with REBETOL® (ribavirin, USP ... - Yahoo! News

Schering-Plough Reports Financial Results for First Quarter of ...  Apr 20, 2006
Sales of the company's PEG-INTRON and REBETOL hepatitis C products rose in the 2006 first quarter, driven by growth in Japan due to a new indication for the ... - PR Newswire

(PRN) - Leading Western and Eastern European Automotive Logistics ...  Apr 28, 2006
...(PRN) - WIN-R Study Demonstrates Efficacy of Shorter PEG-INTRON and REBETOL Regimen in Hepatitis C Patients with Genotype 2 or 3 Virus ... [+. ... - Bolsamania.com

Schering-Plough profit triples, beats forecasts  Apr 20, 2006
Japan. Revenue from Schering-Plough's other hepatitis C drug, the pill Rebetol (ribavirin), rose 22 percent to $78 million. Revenue ... - Reuters

Update 1: Schering-Plough Quarterly Earnings Triple  Apr 20, 2006
Global sales of hepatitis C products rose in the first quarter, with Peg-Intron up 16 percent to $196 million, and Rebetol up 22 percent to $78 million. ... - Forbes

Earnings Roundup: First-quarter earnings triple at Schering  Apr 20, 2006
Schering-Plough's other hepatitis C drug, the pill Rebetol, rose 22 percent, to $78 million, and cancer drug Temodar grew 25 percent, to $163 million. ... - Newark Star Ledger

-- Five-Year Follow-Up Data Demonstrate Sustained Viral Response ...  Apr 25, 2006
...pegylated version of interferon alfa-2b called PEGINTRON (peginterferon alfa-2b), for use as monotherapy or in combination therapy with REBETOL(R) (ribavirin ... - Europa Press





Novartis Licenses Hep C Drug  Mar 29, 2006
Roche makes a $1.38-billion combination treatment for the disease called Pegasys/Copegus. Schering-Plough makes Peg-Intron/Rebetol, worth $1.1 billion a year. ... - Red Herring

Hepatitis C Market: Plenty Of Potential, But Little Progress  Mar 31, 2006
One of those drugs is Ribavirin. It's an oral antiviral sold generically and as Copegus by Roche and Rebetol by Schering-Plough. (SGP). ... - Investor's Business Daily (subscription)

Human Genome Sciences: challenging the pegylated interferons  Mar 15, 2006
...consisting of pegylated interferon (pegIFN) and ribavirin (RBV), marketed by Roche and Schering-Plough as Pegasys/Copegus and PegIntron/Rebetol, respectively. ... - Pharmaceutical Business Review

SP rises on deal and analyst upgrades  Mar 21, 2006
...candidates should be a welcome addition to SP's hepatitis C has portfolio, the marketed end of which has suffered since the demise of Rebetol (ribavirin) to ... - Pharma Times (subscription)

Schering-Plough Reports FDA Grants Fast Track Designation to Oral ...  Jan 31, 2006
PEG-Intron is approved in the United States as monotherapy and for use in combination therapy with Rebetol(R) (ribavirin, USP) for the treatment of chronic ... - DG News

Schering-Plough Reports FDA Grants Fast Track Designation to Oral ...  Jan 30, 2006
...chronic hepatitis C. About PEG-INTRON PEG-INTRON is approved in the United States as monotherapy and for use in combination therapy with REBETOL(R) (ribavirin ... - PR Newswire

Schering-Plough Reports FDA Grants Fast Track Designation to Oral ...  Jan 30, 2006
PEG-INTRON is approved in the United States as monotherapy and for use in combination therapy with REBETOL(R) (ribavirin, USP) for the treatment of chronic ... - PR Newswire

Schering-Plough Swings to Profit  Jan 30, 2006
Hassan said. Fourth quarter sales growth was driven by prescription pharmaceuticals, Peg-Intron, Rebetol, Nasonex and Remicade. The ... - TheStreet.com

Schering-Plough Reports Financial Results for 2005 Fourth Quarter ...  Jan 30, 2006
...the US cholesterol management market (based on December 2005 new prescriptions, IMS data); * Successfully launching PEG-INTRON and REBETOL combination therapy ... - MSN Money

Schering-Plough swings to profit  Jan 30, 2006
...continued market growth. Sales of the Peg-Intron and Rebetol hepatitis C products were driven by higher sales in Japan. Fourth-quarter ... - MarketWatch

Schering-Plough Reports Financial Results For 2005  Jan 31, 2006
...period. The sales increase was driven by the growth of prescription pharmaceuticals, led by PEG-INTRON, REBETOL, NASONEX and REMICADE. ... - CattleNetwork.com

Schering-Plough swings to profit  Jan 30, 2006
Sales growth of the hepatitis C drugs Peg-Intron and Rebetol was driven by Japan. Fourth-quarter global sales of Peg-Intron were up 55% to $214 million. ... - Investor's Business Daily (subscription)

Speed the Plough  Jan 30, 2006
Remicade is still the largest single contributor and continues to grow (up 19% this quarter), while other drugs like PEG-Intron, Rebetol, Temodar, and Nasonex ... - MSNBC

Older HCV Patients Have Tough Time with Combination Therapy  Jan 9, 2006
...infections are less likely than younger patients to tolerate combination therapy with Intron A (recombinant IFN alfa-2b) and Rebetol (ribavirin), researchers ... - MedPage Today

Schering-Plough Reports FDA Grants Fast Track Designation to Oral ...  Jan 30, 2006
PEGINTRON and REBETOL (ribavirin) combination therapy for chronic hepatitis C was approved in the European Union in March 2001. ... - Finanzen.net

Increase ribavirin dose for better HCV treatment response in ...  Jan 18, 2006
...to hepatitis C virus (HCV) treatment, individuals coinfected with HIV and HCV should increase their dose of ribavirin (Copegus / Rebetol / Virazole), according ... - Aidsmap

Fatigue may be misdiagnosed as depression during anti-HCV therapy ...  Jan 23, 2006
...growth factor supplementation) in individuals receiving pegylated interferon alfa-2b (Viraferon-Peg / Peg-Intron) and ribavirin (Copegus / Rebetol / Virazole). ... - Aidsmap

Schering-Plough to evaluate Peg-Intron in combined disease  Jan 16, 2006
Peg-Intron is currently approved in the United States as monotherapy and for use in combination therapy with Rebetol for the treatment of chronic hepatitis C ... - Pharmaceutical Business Review

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional